Evidence map›Paper›PMID 30388216›Full record

ArticleEndocrinology2019

HIF2A-LOX Pathway Promotes Fibrotic Tissue Remodeling in Thyroid-Associated Orbitopathy.

Fumihito Hikage, Stephen Atkins, Alon Kahana, Terry J Smith, Tae-Hwa Chun

Open access · bronzeAbstract read
In one paragraph

Article in Endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 85 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Inhibition of mTOR differently modulates planar and subepithelial fibrogenesis in human conjunctival fibroblasts.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Fumihito HikageDivision of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
Stephen AtkinsDepartment of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan.
Alon KahanaDepartment of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan.
Terry J SmithDivision of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
Tae-Hwa ChunDivision of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
University of Michigan · USSapporo Medical University · JP

Funding

REGULATION OF RETROOCULAR CONNECTIVE TISSUER01EY008976 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SMITH, TERRY J · 1993 to 2020
$6.4M
MMP14-dependent regulation of adipose tissue remodeling and function (R01)R01DK095137 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHUN, TAEHWA · 2012 to 2016
$1.7M
University of Michigan Autoimmunity Center of Excellence, Clinical Research ProgrUM1AI110557 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FOX, DAVID ALAN · 2014 to 2018
$543k
NEI NIH HHS R01 EY008976NIAID NIH HHS UM1 AI110557NIDDK NIH HHS R01 DK095137
6 · The paper itself

Abstract

Thyroid-associated orbitopathy (TAO) is a disfiguring periocular connective tissue disease associated with autoimmune thyroid disorders. It is a potentially blinding condition, for which no effective pharmacological treatment has been established. Despite a suggested role played by autoimmune thyrotropin receptor activation in the pathogenesis of TAO, the cellular and molecular events contributing to the fibrotic and inflammatory disease process of TAO are not fully defined. By developing a three-dimensional organoid culture of human orbital fibroblasts (OFs), we sought to determine the molecular mechanism underlying the fibrotic disease process of TAO. In this ex vivo model, we have demonstrated that hypoxia-inducible factor (HIF) 2α (HIF2A), but not its paralog HIF1A, accelerates extracellular matrix (ECM) deposition by inducing a collagen-cross-linking enzyme, lysyl oxidase (LOX). Inhibiting HIF2A and LOX with short hairpin RNA or small molecular antagonists effectively ameliorated fibrotic disease process within TAO organoids. Conversely, the overexpression of a constitutively active HIF2A in mouse OFs was sufficient to initiate LOX-dependent fibrotic tissue remodeling in OF organoids. Consistent with these findings, HIF2A and LOX were highly expressed in human TAO tissues paralleling excess ECM deposition. We propose that the HIF2A-LOX pathway can be a potential therapeutic target for the prevention and treatment of TAO.

Indexed as

AnimalsBasic Helix-Loop-Helix ProteinsCells, CulturedCollagenEndothelial PAS Domain-Containing Protein 1Extracellular MatrixExtracellular Matrix ProteinsFibroblastsFibrosisGraves OphthalmopathyHumansIn Vitro TechniquesMiceProtein-Lysine 6-OxidaseBasic Helix-Loop-Helix ProteinsCollagenEndothelial PAS Domain-Containing Protein 1Extracellular Matrix ProteinsLox protein, mouseProtein-Lysine 6-Oxidase

Identifiers

PMID30388216
PMCPMC6293089
OpenAlexW2899444928

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.